8-K
filed September 8, 2022, 7:59 PM ET
ticker QTTB
CIK 0001661998
leadership
confidence high
sentiment neutral
materiality 0.70
Homology Medicines appoints Albert Seymour as CEO; Arthur Tzianabos named Chairman
Q32 Bio Inc.
- Albert Seymour, former CSO and President, promoted to CEO; base salary raised to $570,000, bonus target 55%.
- Seymour received option for 23,000 shares at $2.18 and 14,000 RSUs, vesting over 48 months and 3 years.
- Arthur Tzianabos resigned as CEO, appointed Chairman of Board; consulting agreement pays $26,571/month through March 31, 2023.
- Kush Parmar resigned from Board and Chairman role; Jeffrey Poulton appointed Lead Director.
- CFO W. Bradford Smith's severance amended: 12 months base salary continuation on qualifying termination.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Albert Seymour was appointed as Class II Director at Q32 Bio Inc..
- Action
- appointed
- Role
- Class II Director
Exact text from the filing
Also on September 6, 2022, the Board appointed Albert Seymour, Ph.D. as a Class II director of the Company, replacing Kush M. Parmar, M.D., Ph.D., who resigned from his position as a member of the Board and as Chairman of the Board on the same date.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jeffrey V. Poulton was appointed as Lead Director at Q32 Bio Inc..
- Action
- appointed
- Role
- Lead Director
Exact text from the filing
and has also appointed Jeffrey V. Poulton to serve as the Lead Director of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Arthur O. Tzianabos was appointed as Chairman of the Board at Q32 Bio Inc..
- Action
- appointed
- Role
- Chairman of the Board
Exact text from the filing
The Board has appointed Arthur O. Tzianabos, Ph.D. to replace Dr. Parmar as the Chairman of the Board
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Arthur O. Tzianabos resigned as Chief Executive Officer at Q32 Bio Inc..
- Action
- resigned
- Role
- Chief Executive Officer
Exact text from the filing
On September 6, 2022, in connection with Dr. Seymour’s promotion, Dr. Tzianabos notified the Company of his resignation as Chief Executive Officer.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Albert Seymour was appointed as Chief Executive Officer at Q32 Bio Inc..
- Action
- appointed
- Role
- Chief Executive Officer
Exact text from the filing
On September 6, 2022, the Board of Directors (the “ Board ”) of Homology Medicines, Inc. (the “ Company ”) appointed Albert Seymour, Ph.D., the Company’s former Chief Scientific Officer and President, to serve as the Company’s Chief Executive Officer, in addition to his role as the Company’s President.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kush M. Parmar resigned as Chairman of the Board at Q32 Bio Inc..
- Action
- resigned
- Role
- Chairman of the Board
Exact text from the filing
Also on September 6, 2022, the Board appointed Albert Seymour, Ph.D. as a Class II director of the Company, replacing Kush M. Parmar, M.D., Ph.D., who resigned from his position as a member of the Board and as Chairman of the Board on the same date.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.